RxDoctor Payments Data

Tasneen Mohammad

Dermatology · Detroit, MINPI 1962820696

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,525 of the $8,892 with a category attached, or 73.4%. Incyte Corporation accounts for 76.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $7,628 and has fallen 98.3% since, to $129 in 2025.

$8,892in general payments, 2019–2025

Across 29 payments — averaging $306.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$7K
  • Avita Medical Americas, LLC$764
  • Novartis$237
  • AbbVie$217
  • Johnson & Johnson$170
  • LEO Pharma Inc.$137
  • plus $605 from 6 others
$52,730in research payments, 2019–2025

Across 10 payments — averaging $5273.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Tanabe Pharma America, Inc.$50K
  • Pfizer$3K

What the payments were for

  • Consulting fees$6,52573%
  • Travel & lodging$85610%
  • Food & beverage$1,41116%
  • Education$1001%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,892 in reported general payments places this provider in the 80th percentile of 404 dermatology providers in Michigan.

See all dermatology providers in Michigan

Medicare billing

Part B allowed, 2024
$22,056
Medicare patients
136
Services billed
383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast30$136,656
Humira PenAdalimumab12$71,704
RinvoqUpadacitinib11$67,960
OpzeluraRuxolitinib Phosphate21$39,667
Calcipotriene21$3,892
Clobetasol Propionate64$1,708
Tacrolimus13$1,325
Ketoconazole80$1,299
Triamcinolone Acetonide80$1,053
Ammonium Lactate40$928
Clindamycin Phosphate26$685
Fluocinolone Acetonide19$616
Metronidazole16$517
Doxycycline Hyclate29$464
Hydrocortisone55$329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$217$67,96011 claims
Incyte CorporationOpzelura$6,761$39,66721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 404 dermatology providers in Michigan.

Other dermatology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →